Skip to main content

SciClone IPOs on Hong Kong Exchange, Raising $279 Million

SciClone Pharma, a Shanghai in-licensing company, staged a Hong Kong IPO that raised $279 million. Previously listed in the US , SciClone was privatized in 2017 for $605 million. The IPO valued the company at $1.6 billion. SciClone plans to use the proceeds to in-license additional products and fund clinical development of its existing assets. Its major marketed product is Zadaxin ® (thymalfasin), an immune system adjuvant that is used to treat hepatitis B, though SciClone says it was also proved helpful for SARS and COVID-19. More details.... Stock Symbol: (HK: 6600) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.